Harvard Bioscience, Inc. · NASDAQ:HBIO

Harvard Bioscience — Investor Presentation (January 2026)

15 slides from Harvard Bioscience's investor presentation, January 2026

  1. Slide 1: HBIO Investor Overview

    NASDAQ: HBIO HBIO Investor Overview January 2026 HBio Confidential 1

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information Forward Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified

  3. Slide 3: Solid Operating Platform to Support Growth & Improved Profitability

    Solid Operating Platform to Support Growth & Improved Profitability  Leading global tools provider with wide range of pre-clinical workflows and applications in several growth markets  Largest business unit (Preclinical) with #1 position in high demand animal telemetry tools market  Leader in rap

  4. Slide 4: HBio at a Glance

    HBio at a Glance What does HBio do? Who does HBio serve? Cellular & Molecular Academic / Biotech / CRO / Preclinical Systems Americas | EMEA | APAC Technology (CMT) Research Pharma Gov. Data acquisition, processing, and Technologies and tools necessary regulatory report generation for for research,

  5. Slide 5: 2025 Goals & Performance

    2025 Goals & Performance Q3 results demonstrated operational progress, consistent execution, and tangible improvement in several key areas of our business Priorities for 2025:  Maintain financial discipline and positive cash generation  Accelerate product adoption across our core growth platforms

  6. Slide 6: HBio Investment Highlights

    HBio Investment Highlights 1 Broad portfolio serves as one stop shop Leading provider for academic research, DIVERSIFIED CUSTOMER / for customers CROs & biotech / pharma customers REVENUE MODEL Systems & Software 2 Leading reputation, with multiple High barrier competitive advantages innovative tech

  7. Slide 7: Broad Portfolio Serves as One Stop Shop for Customers

    Broad Portfolio Serves as One Stop Shop for Customers Leading provider of products across the drug development cycle, spanning research and discovery, bioproduction and preclinical testing Preclinical Systems Products New: SoHo Implantable Telemetry System Measurement of biopotentials in small lab a

  8. Slide 8: Leading Reputation, with Multiple Competitive Advantages

    Leading Reputation, with Multiple Competitive Advantages HBio’s approach is powered by a unique product portfolio across the drug development cycle that drive differentiation beyond the products themselves First Mover Advantage Sticky Revenue • First commercial in-vitro microelectrode array • Many p

  9. Slide 9: Long Standing Relationships with Blue-Chip Customers

    Long Standing Relationships with Blue-Chip Customers ACADEMIC CONTRACT RESEARCH BIOTECH, RESEARCH ORGANIZATIONS PHARMACEUTICAL  Scientific Research labs primarily  Preclinical studies to determine safety and  Perform early discovery and then government & grant funded efficacy of new pharmaceutica

  10. Slide 10: Strong Global Footprint

    Strong Global Footprint HBio’s global infrastructure provides a strong platform for further investment and growth  Manufactures and tests majority of products in principal facilities in the NEUROSCIENCE United States, Germany and Spain RESEARCH Barcelona, Spain  Operations primarily involve CELLUL

  11. Slide 11: Exciting New Product Introduction (NPI) Pipeline Provides Numerous High Growth Opportunities

    Exciting New Product Introduction (NPI) Pipeline Provides Numerous High Growth Opportunities STRENGTHEN THE BASE: DELIVER > MARKET GROWTH SIGNIFICANT INVESTMENT MADE, GROWTH TO FOLLOW Bio-Production In-Vitro Organoid Apps PRECLINICAL CMT CMT - ORGANOIDS • Ponemah Enterprise Data Acquisition/Analysis

  12. Slide 12: Strong Management Team

    Strong Management Team Supported by highly experienced employee base with nearly a third holding MS / PhDs John Duke Mark Frost Ryan Wallace President & CEO Interim CFO and Treasurer Senior VP Global Sales 25+ years of experience 30 years of finance experience, 20 as CFO 15 years of sales experience

  13. Slide 13: Non-GAAP Reconciliation Table

    Non-GAAP Reconciliation Table 13

  14. Slide 14: Non-GAAP Reconciliation Table

    Non-GAAP Reconciliation Table (1) Other operating expenses for the three months ended March 31, 2025 includes $93 thousand of restructuring-related charges and $171 thousand of employee retention Three Months Ended Three Months Ended Three Months Ended tax credit fees compared to $472 thousand of em

  15. Slide 15: 18

    18

Harvard Bioscience — Investor Presentation (January 2026) on 6ix